Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Payables (2022 - 2026)

Compass Therapeutics' Payables history spans 5 years, with the latest figure at $906000.0 for Q1 2026.

  • On a quarterly basis, Payables fell 42.55% to $906000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $906000.0, a 42.55% decrease, with the full-year FY2025 number at $1.6 million, down 29.52% from a year prior.
  • Payables hit $906000.0 in Q1 2026 for Compass Therapeutics, down from $1.6 million in the prior quarter.
  • Over the last five years, Payables for CMPX hit a ceiling of $4.1 million in Q4 2023 and a floor of $724000.0 in Q2 2023.
  • Historically, Payables has averaged $1.9 million across 5 years, with a median of $1.6 million in 2025.
  • Biggest five-year swings in Payables: tumbled 58.37% in 2024 and later surged 222.4% in 2025.
  • Tracing CMPX's Payables over 5 years: stood at $3.4 million in 2022, then increased by 20.93% to $4.1 million in 2023, then crashed by 45.01% to $2.2 million in 2024, then dropped by 29.52% to $1.6 million in 2025, then tumbled by 42.84% to $906000.0 in 2026.
  • Business Quant data shows Payables for CMPX at $906000.0 in Q1 2026, $1.6 million in Q4 2025, and $3.1 million in Q3 2025.